Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$22.20
-1.2%
$21.67
$12.21
$41.31
$652.24M-0.26639,003 shs525,155 shs
Aptorum Group Limited stock logo
APM
Aptorum Group
$0.91
-6.3%
$0.98
$0.46
$7.49
$4.87M-0.14619,769 shs37,769 shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$3.92
+6.2%
$4.00
$3.21
$8.06
$937.90M0.64.49 million shs5.16 million shs
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$18.12
+4.7%
$14.21
$7.75
$19.93
$138.44M0.5527,305 shs91,780 shs
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$827.94
+1.1%
$714.97
$279.02
$830.21
$64.46B1.29711,439 shs529,854 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
0.00%-3.02%+0.09%+20.87%-10.34%
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%-1.87%+7.82%+15.65%-77.83%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.00%+3.65%-0.81%-24.85%-50.20%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
0.00%-0.46%+21.39%+81.07%+26.17%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
0.00%+5.31%+10.08%+55.64%+178.21%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.2706 of 5 stars
3.41.00.00.03.21.70.6
Aptorum Group Limited stock logo
APM
Aptorum Group
0.811 of 5 stars
0.03.00.00.02.11.70.6
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.4436 of 5 stars
3.53.00.04.42.72.50.6
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.7685 of 5 stars
3.33.00.04.71.80.80.0
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
1.1941 of 5 stars
1.43.00.00.03.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.80
Moderate Buy$42.3890.88% Upside
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00
N/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89177.78% Upside
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.67
Moderate Buy$33.0082.12% Upside
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.75
Moderate Buy$699.55-15.51% Downside

Current Analyst Ratings Breakdown

Latest ARDX, AXON, APM, ASMB, and ANAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
6/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$22.00 ➝ $38.00
6/4/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$750.00 ➝ $895.00
5/29/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
5/28/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $90.00
5/14/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$730.00 ➝ $830.00
5/9/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$726.00 ➝ $735.00
5/8/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$600.00 ➝ $750.00
5/6/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $54.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$11.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$111.87M5.83N/AN/A$2.33 per share9.53
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K11.32N/AN/A$2.20 per share0.41
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M2.81N/AN/A$0.73 per share5.37
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$28.52M4.85N/AN/A$5.25 per share3.45
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$2.23B28.95$2.82 per share293.83$30.52 per share27.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)
Aptorum Group Limited stock logo
APM
Aptorum Group
-$4.27MN/A0.00N/AN/AN/AN/A7/30/2025 (Estimated)
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A12.65N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$40.18M-$6.23N/AN/AN/A-124.15%-131.77%-36.81%8/6/2025 (Estimated)
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$377.03M$4.14199.99248.6394.2314.86%5.81%2.83%8/5/2025 (Estimated)

Latest ARDX, AXON, APM, ASMB, and ANAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$2.01-$1.17+$0.84-$1.17$7.41 million$9.42 million
5/7/2025Q1 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.34$1.41+$0.07$1.08$585.67 million$603.63 million
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
8.25
8.25
Aptorum Group Limited stock logo
APM
Aptorum Group
N/A
0.22
0.22
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
2.05
2.05
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
0.68
2.83
2.62

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
79.08%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.50%
Aptorum Group Limited stock logo
APM
Aptorum Group
63.99%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
5.10%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million19.54 millionOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
305.35 million1.93 millionNot Optionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
1007.64 million7.25 millionOptionable
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2,15077.85 million73.41 millionOptionable

Recent News About These Companies

Analysts Set Axon Enterprise, Inc (NASDAQ:AXON) PT at $699.55

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$22.20 -0.27 (-1.20%)
As of 04:00 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Aptorum Group stock logo

Aptorum Group NASDAQ:APM

$0.91 -0.06 (-6.33%)
As of 03:48 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$3.92 +0.23 (+6.23%)
As of 04:00 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$18.12 +0.81 (+4.68%)
As of 04:00 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Axon Enterprise stock logo

Axon Enterprise NASDAQ:AXON

$827.94 +9.34 (+1.14%)
As of 04:00 PM Eastern

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.